We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Diabetes Researchers Convert Stem Cells into Insulin-Producing Cells

By LabMedica International staff writers
Posted on 11 Dec 2018
Print article
Image: Endodermal cells, they form organs such as lung, liver and pancreas (Photo courtesy of IDR, Helmholtz Zentrum München).
Image: Endodermal cells, they form organs such as lung, liver and pancreas (Photo courtesy of IDR, Helmholtz Zentrum München).
A team of stem cell biologists working on the problem of pancreas replacement in patients with type I diabetes identified the extrinsic and intrinsic signaling mechanisms that coordinate the fate-determining transcriptional events underlying the maturation of bipotent pancreatic progenitors and used this information to convert these pancreatic progenitors - derived from human embryonic stem cells - to insulin-producing islet cells.

The pancreas originates from two epithelial evaginations (meaning to turn an organ or part inside out) of the foregut, which consist of multipotent epithelial progenitor cells that organize into a complex tubular epithelial network. The trunk domain of each epithelial branch consists of bipotent pancreatic progenitors that give rise to both duct and endocrine lineages.

Investigators at Helmholtz Zentrum München (Munich, Germany) reported in the November 28, 2018, online edition of the journal Nature that single-cell analysis of pancreatic bipotent pancreatic progenitors derived from human embryonic stem cells revealed that cell confinement was a prerequisite for endocrine specification, whereas spreading drove the progenitors towards a ductal fate. Mechanistic studies identified the interaction of extracellular matrix (ECM) with integrin alpha5 as the extracellular cue that controlled the fate of bipotent pancreatic progenitors.

While ECM-integrin alpha5 signaling promoted differentiation towards the duct lineage, disruption of this signaling cascade stimulated hormone development. This cascade could be disrupted genetically or with drugs to convert bipotent pancreatic progenitors derived from human embryonic stem cells into hormone-producing islet cells.

"We have now been able to map the signal that determines whether pancreatic progenitor cells will become endocrine, such as insulin-producing beta cells or duct cells", said senior author Dr. Henrik Semb, director of the institute of translational stem cell research at Helmholtz Zentrum München. "The cells are analogous to pinballs, whose ultimate score is based on the sum of pin encounters. They are constantly moving around within the developing pancreas, leading to frequent environmental changes. We show that the exposure to specific extracellular matrix components determines the ultimate destiny of the cells."

"We can now replace significant numbers of empirically derived substances, whose mode of action in current state-of-the-art differentiation protocols is largely unknown, with small molecule inhibitors that target specific components of the newly identified mechano-signaling pathway," said Dr. Semb. "Our discovery breaks new ground because it explains how multipotent progenitor cells mature into different cell types during organ formation. It also gives us the tools to recreate the processes in the laboratory, to more precisely engineer cells that are lost or damaged in severe diseases, such as type I diabetes and neurodegenerative diseases, for future cell replacement therapies."

Related Links:
Helmholtz Zentrum München

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Biological Indicator Vials
BI-O.K.
New
Immunofluorescence Analyzer
MPQuanti

Print article

Channels

Clinical Chemistry

view channel
Image: The research team has developed the uCR-Chip device to enhance kidney function testing (Photo courtesy of University of Manitoba)

Low-Cost Portable Screening Test to Transform Kidney Disease Detection

Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.